🇺🇸 FDA
Patent

US 12221627

Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells

granted A61KA61K2239/50A61K40/11

Quick answer

US patent 12221627 (Methods of enriching cell populations for cancer-specific T cells using in vitro stimulation of memory T cells) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K2239/50, A61K40/11, A61K40/32, A61K40/4257